cCalculated with NIAD market volume (previously GLP-1) to prepare for RYBELSUS® access calculations. Note: Data from VANTAGE FingerTip Formulary bridge/February 2021 Nomenclature, and Xponent PlanTrak using week ending 3/05/2021; only considers bridged volume; excludes cash and mail order data; based on full DCS/EDCS/OCS IC universe (targets + non-targets).
dNovo Nordisk defines access as covered when brand is available on formulary with or without restrictions. Coverage status and tier vary by plan and are subject to change. Please check directly with the health plan to confirm coverage for individual patients.
ePlan data based on number of pharmacy lives as reported by Fingertip Formulary® (current as of May 2020). Applies to commercial business only. Formulary status is subject to change. Because formularies do change, and many health plans offer more than one formulary, please check directly with the health plan to confirm coverage for individual patients. 2020 Fingertip Formulary®.
All rights reserved.